Korro Bio Inc
KRRO12.570USD
+1.030+8.93%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
118.13MMarket Cap
LossP/E TTM
More Details of Korro Bio Inc Company
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc Info
Ticker SymbolKRRO
Company nameKorro Bio Inc
IPO dateOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Number of employees104
Security typeOrdinary Share
Fiscal year-endOct 03
AddressOne Kendall Square. Building 600-700
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16174681999
Websitehttps://www.korrobio.com/
Ticker SymbolKRRO
IPO dateOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Company Executives of Korro Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
21.48K
+21482.00%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
20.13K
+20132.00%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.09M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Feb 3
Updated: Tue, Feb 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
Other
55.43%
Shareholders
Shareholders
Proportion
Atlas Venture
12.08%
New Enterprise Associates (NEA)
11.58%
Lynx1 Capital Advisors LLC
7.79%
Driehaus Capital Management, LLC
7.14%
Fidelity Management & Research Company LLC
5.99%
Other
55.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
51.04%
Venture Capital
24.12%
Hedge Fund
23.88%
Investment Advisor/Hedge Fund
15.43%
Corporation
5.74%
Research Firm
2.19%
Individual Investor
1.96%
Private Equity
0.34%
Bank and Trust
0.26%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
191
11.02M
117.07%
+1.11M
2025Q3
186
9.33M
99.33%
-1.07M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Atlas Venture
1.14M
12.08%
--
--
Sep 30, 2025
New Enterprise Associates (NEA)
1.09M
11.58%
--
--
Sep 30, 2025
Lynx1 Capital Advisors LLC
733.63K
7.79%
+733.63K
--
Dec 23, 2025
Driehaus Capital Management, LLC
671.98K
7.14%
+91.12K
+15.69%
Sep 30, 2025
Fidelity Management & Research Company LLC
563.68K
5.99%
-75.54K
-11.82%
Sep 30, 2025
Platanus Investment LLC
540.16K
5.74%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
531.97K
5.65%
-8.11K
-1.50%
Sep 30, 2025
The Vanguard Group, Inc.
395.66K
4.2%
+8.92K
+2.31%
Sep 30, 2025
Cormorant Asset Management, LP
465.00K
4.94%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Date
Ex-dividend Date
Type
Ratio
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
